Laidlaw & Co. Initiates Coverage On IN8bio with Buy Rating, Announces Price Target of $7.5
Portfolio Pulse from Benzinga Newsdesk
Laidlaw & Co. analyst Yale Jen has initiated coverage on IN8bio (NASDAQ:INAB) with a Buy rating and set a price target of $7.5.
March 18, 2024 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Laidlaw & Co. initiated coverage on IN8bio with a Buy rating and a price target of $7.5.
The initiation of coverage by a reputable analyst with a Buy rating and a specific price target usually signals confidence in the company's future performance. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100